---
sidebar_position: 2
---

# æ–‡ç» 2ï¼šThe clinical application potential assessment of the Deepseek-R1 large language model in lung cancer

**English Title**: The clinical application potential assessment of the Deepseek-R1 large language model in lung cancer

**ä¸­æ–‡æ¨™é¡Œ**: Deepseek-R1 å¤§å‹èªè¨€æ¨¡å‹åœ¨è‚ºç™Œä¸­çš„è‡¨åºŠæ‡‰ç”¨æ½›åŠ›è©•ä¼°
**PMID**: 40963861
**æœŸåˆŠ**: Frontiers in oncology
**è©•åˆ†**: 8
**æ‡‰ç”¨é ˜åŸŸ**: é–€è¨º
**DOI**: https://doi.org/10.3389/fonc.2025.1601529

---

## ğŸ“Œ ç¬¬ä¸€å¼µï¼šæ ¸å¿ƒè§€é»å¡

### ä¸»è¦ç™¼ç¾
Deepseek-R1åœ¨è…«ç˜¤ç§‘çš„å°ˆé–€æ‡‰ç”¨

### æ–‡ç»æ‘˜è¦ï¼ˆAbstractï¼‰
BACKGROUND: This study evaluates the clinical potential of the large language model Deepseek-R1 in the diagnosis and treatment of lung cancer, with a specific focus on its ability to assist junior oncologists. The research systematically assesses the model's performance in terms of diagnostic accuracy, consistency of treatment recommendations, and reliability in clinical decision-making. METHODS: A total of 320 patients newly diagnosed with lung cancer were included in this retrospective study. Twenty-six structured clinical questions were designed based on international diagnostic and treatment guidelines. These questions addressed three key domains: basic medical knowledge, complex clinical decision-making, and ethical judgment. All patient data were anonymized before being entered into the Deepseek-R1 model. The model's responses, along with those generated by five junior oncologists with no more than three years of clinical experience, were independently assessed by senior oncologists with over ten years of experience. A double-blind evaluation protocol was implemented to reduce potential assessment bias. Inter-rater agreement was quantified using Cohen's Kappa coefficient. RESULTS: In the categories of basic knowledge, advanced clinical decisions, and ethical questions, Deepseek-R1 achieved average accuracy rates of 92.3%, 87.5%, and 85.1%, respectively. These rates were significantly higher than those of junior oncologists, whose accuracy rates were 80.4%, 72.8%, and 70.2%, respectively (P &lt; 0.05). In a sample of 256 cases evaluated formally, Deepseek-R1's overall diagnostic accuracy was 94.6%, compared to 78.9% for junior oncologists (P &lt; 0.05). In a longitudinal assessment of 40 cases with disease progression, the model demonstrated high consistency in updating its recommendations. Logical errors were more frequent among junior oncologists, while ethical risks appeared more commonly in the model-generated responses (44% vs. 21.9%). CONCLUSION: Deepseek-R1 significantly outperformed junior oncologists in terms of diagnostic accuracy and treatment decision-making, particularly in complex and dynamic clinical situations. While limitations remain in its ethical reasoning, the model holds substantial potential for supporting junior physicians, contributing to multidisciplinary discussions, and optimizing treatment pathways.

### ä¸­æ–‡æ‘˜è¦
èƒŒæ™¯ï¼šæœ¬ç ”ç©¶è©•ä¼°å¤§å‹èªè¨€æ¨¡å‹ Deepseek-R1 åœ¨è‚ºç™Œè¨ºæ–·å’Œæ²»ç™‚ä¸­çš„è‡¨åºŠæ½›åŠ›ï¼Œç‰¹åˆ¥é—œæ³¨å…¶å”åŠ©åˆç´šè…«ç˜¤ç§‘é†«å¸«çš„èƒ½åŠ›ã€‚ç ”ç©¶ç³»çµ±æ€§åœ°è©•ä¼°è©²æ¨¡å‹åœ¨è¨ºæ–·æº–ç¢ºæ€§ã€æ²»ç™‚å»ºè­°ä¸€è‡´æ€§å’Œè‡¨åºŠæ±ºç­–å¯é æ€§æ–¹é¢çš„è¡¨ç¾ã€‚æ–¹æ³•ï¼šæœ¬å›é¡§æ€§ç ”ç©¶ç´å…¥ 320 åæ–°è¨ºæ–·è‚ºç™Œæ‚£è€…ã€‚åŸºæ–¼åœ‹éš›è¨ºæ–·å’Œæ²»ç™‚æŒ‡å¼•è¨­è¨ˆäº† 26 å€‹çµæ§‹åŒ–è‡¨åºŠå•é¡Œï¼Œæ¶µè“‹ä¸‰å€‹é—œéµé ˜åŸŸï¼šåŸºç¤é†«å­¸çŸ¥è­˜ã€è¤‡é›œè‡¨åºŠæ±ºç­–å’Œå€«ç†åˆ¤æ–·ã€‚æ‰€æœ‰æ‚£è€…è³‡æ–™åœ¨è¼¸å…¥ Deepseek-R1 æ¨¡å‹å‰å‡å·²åŒ¿ååŒ–è™•ç†ã€‚è©²æ¨¡å‹çš„å›æ‡‰èˆ‡äº”ä½è‡¨åºŠç¶“é©—ä¸è¶…éä¸‰å¹´çš„åˆç´šè…«ç˜¤ç§‘é†«å¸«çš„å›æ‡‰ï¼Œç”±å…·æœ‰åå¹´ä»¥ä¸Šç¶“é©—çš„è³‡æ·±è…«ç˜¤ç§‘é†«å¸«ç¨ç«‹è©•ä¼°ã€‚æ¡ç”¨é›™ç›²è©•ä¼°æ–¹æ¡ˆä»¥é™ä½æ½›åœ¨çš„è©•ä¼°åå·®ï¼Œè©•ä¼°è€…é–“ä¸€è‡´æ€§ä½¿ç”¨ Cohen's Kappa ä¿‚æ•¸é‡åŒ–ã€‚çµæœï¼šåœ¨åŸºç¤çŸ¥è­˜ã€é€²éšè‡¨åºŠæ±ºç­–å’Œå€«ç†å•é¡Œé¡åˆ¥ä¸­ï¼ŒDeepseek-R1 çš„å¹³å‡æº–ç¢ºç‡åˆ†åˆ¥ç‚º 92.3%ã€87.5% å’Œ 85.1%ï¼Œé¡¯è‘—é«˜æ–¼åˆç´šè…«ç˜¤ç§‘é†«å¸«çš„ 80.4%ã€72.8% å’Œ 70.2%ï¼ˆP < 0.05ï¼‰ã€‚åœ¨æ­£å¼è©•ä¼°çš„ 256 å€‹ç—…ä¾‹æ¨£æœ¬ä¸­ï¼ŒDeepseek-R1 çš„æ•´é«”è¨ºæ–·æº–ç¢ºç‡ç‚º 94.6%ï¼Œè€Œåˆç´šè…«ç˜¤ç§‘é†«å¸«ç‚º 78.9%ï¼ˆP < 0.05ï¼‰ã€‚åœ¨å° 40 å€‹ç–¾ç—…é€²å±•ç—…ä¾‹çš„ç¸±å‘è©•ä¼°ä¸­ï¼Œè©²æ¨¡å‹åœ¨æ›´æ–°å»ºè­°æ™‚å±•ç¾é«˜åº¦ä¸€è‡´æ€§ã€‚åˆç´šè…«ç˜¤ç§‘é†«å¸«è¼ƒå¸¸å‡ºç¾é‚è¼¯éŒ¯èª¤ï¼Œè€Œæ¨¡å‹ç”Ÿæˆçš„å›æ‡‰ä¸­å€«ç†é¢¨éšªè¼ƒç‚ºå¸¸è¦‹ï¼ˆ44% vs. 21.9%ï¼‰ã€‚çµè«–ï¼šDeepseek-R1 åœ¨è¨ºæ–·æº–ç¢ºæ€§å’Œæ²»ç™‚æ±ºç­–æ–¹é¢é¡¯è‘—å„ªæ–¼åˆç´šè…«ç˜¤ç§‘é†«å¸«ï¼Œç‰¹åˆ¥æ˜¯åœ¨è¤‡é›œå’Œå‹•æ…‹çš„è‡¨åºŠæƒ…å¢ƒä¸­ã€‚å„˜ç®¡åœ¨å€«ç†æ¨ç†æ–¹é¢ä»æœ‰å±€é™æ€§ï¼Œè©²æ¨¡å‹åœ¨æ”¯æŒåˆç´šé†«å¸«ã€ä¿ƒé€²å¤šå­¸ç§‘è¨è«–å’Œå„ªåŒ–æ²»ç™‚è·¯å¾‘æ–¹é¢å…·æœ‰ç›¸ç•¶å¤§çš„æ½›åŠ›ã€‚

### é—œéµæ•¸æ“š
- **ç ”ç©¶é¡å‹**: æœªåˆ†é¡
- **åœ‹å®¶/åœ°å€**: å¾…æŸ¥
- **ç™¼è¡¨å¹´ä»½**: å¾…æŸ¥
- **ROI æ•¸å€¼**: ç„¡æ•¸å€¼

### æ ¸å¿ƒå‰µæ–°é»
æœ¬ç ”ç©¶çš„ä¸»è¦å‰µæ–°åœ¨æ–¼ï¼šDeepseek-R1åœ¨è…«ç˜¤ç§‘çš„å°ˆé–€æ‡‰ç”¨

---

## âœï¸ ç¬¬äºŒå¼µï¼šParaphrase å¡

### ç ”ç©¶ç›®çš„èˆ‡æ–¹æ³•
æœ¬ç ”ç©¶èšç„¦æ–¼é–€è¨ºé ˜åŸŸï¼Œæ—¨åœ¨æ¢è¨ AI æŠ€è¡“åœ¨é†«ç™‚å ´æ™¯ä¸­çš„æ‡‰ç”¨ã€‚

### ä¸»è¦è²¢ç»
ç ”ç©¶æå‡ºäº†Deepseek-R1åœ¨è…«ç˜¤ç§‘çš„å°ˆé–€æ‡‰ç”¨ï¼Œç‚ºè‡¨åºŠå¯¦è¸æä¾›äº†æ–°çš„è§£æ±ºæ–¹æ¡ˆã€‚

### æŠ€è¡“ç‰¹é»
- æ‡‰ç”¨å ´æ™¯ï¼šé–€è¨º
- å‰µæ–°ç¨‹åº¦ï¼šè©•åˆ† 8/10
- æœŸåˆŠå½±éŸ¿ï¼šç™¼è¡¨æ–¼ Frontiers in oncology

---

## â“ ç¬¬ä¸‰å¼µï¼šå•ç­”å¡

### Q1: é€™é …ç ”ç©¶è§£æ±ºäº†ä»€éº¼å•é¡Œï¼Ÿ
A: æœ¬ç ”ç©¶é‡å°é–€è¨ºé ˜åŸŸçš„æŒ‘æˆ°ï¼Œæå‡ºäº†åŸºæ–¼ AI çš„è§£æ±ºæ–¹æ¡ˆã€‚

### Q2: æ¡ç”¨äº†ä»€éº¼æŠ€è¡“æ–¹æ³•ï¼Ÿ
A: Deepseek-R1åœ¨è…«ç˜¤ç§‘çš„å°ˆé–€æ‡‰ç”¨

### Q3: ç ”ç©¶çš„ä¸»è¦æˆæœæ˜¯ä»€éº¼ï¼Ÿ
A: ç ”ç©¶ç²å¾—äº† 8 åˆ†çš„å°ˆå®¶è©•åˆ†ï¼Œè­‰æ˜äº†å…¶åœ¨é–€è¨ºé ˜åŸŸçš„æ‡‰ç”¨åƒ¹å€¼ã€‚

### Q4: æœ‰å“ªäº›å¯¦éš›æ‡‰ç”¨å ´æ™¯ï¼Ÿ
A: ä¸»è¦æ‡‰ç”¨æ–¼é–€è¨ºï¼Œå¯ç”¨æ–¼æ”¹å–„é†«ç™‚æœå‹™å“è³ªå’Œæ•ˆç‡ã€‚

---

## ğŸ¤” ç¬¬å››å¼µï¼šä¾‹å¤–å¡

### æ½›åœ¨é™åˆ¶
1. **ç ”ç©¶ç¯„åœ**: ç ”ç©¶è©•åˆ†ç‚º 8/10ï¼Œå¯èƒ½å­˜åœ¨æ”¹é€²ç©ºé–“
2. **åœ°å€å·®ç•°**: ç ”ç©¶ä¾†è‡ªå¾…æŸ¥ï¼Œå…¶ä»–åœ°å€é©ç”¨æ€§éœ€é©—è­‰
3. **ROI æ•¸æ“š**: ç„¡æ•¸å€¼ï¼Œç¶“æ¿Ÿæ•ˆç›Šè©•ä¼°å¯èƒ½ä¸å®Œæ•´

### éœ€è¦é€²ä¸€æ­¥æ¢è¨çš„å•é¡Œ
1. è©²æŠ€è¡“åœ¨ä¸åŒè¦æ¨¡é†«é™¢çš„é©ç”¨æ€§å¦‚ä½•ï¼Ÿ
2. é•·æœŸä½¿ç”¨çš„æ•ˆæœå’Œç©©å®šæ€§æ˜¯å¦ç¶“éé©—è­‰ï¼Ÿ
3. èˆ‡ç¾æœ‰ç³»çµ±æ•´åˆæ™‚å¯èƒ½é¢è‡¨å“ªäº›æŒ‘æˆ°ï¼Ÿ

### æ‰¹åˆ¤æ€§æ€è€ƒ
- **æŠ€è¡“æˆç†Ÿåº¦**: éœ€è¦è©•ä¼°å¾ç ”ç©¶åˆ°å¯¦éš›éƒ¨ç½²çš„è·é›¢
- **æˆæœ¬æ•ˆç›Š**: ç„¡æ•¸å€¼ï¼Œéœ€è¦æ›´è©³ç´°çš„ç¶“æ¿Ÿåˆ†æ
- **å€«ç†è€ƒé‡**: AI åœ¨é–€è¨ºæ‡‰ç”¨æ™‚çš„å€«ç†å’Œéš±ç§å•é¡Œ
- **å¯æ¨å»£æ€§**: ç ”ç©¶çµæœåœ¨å…¶ä»–é†«ç™‚å ´æ™¯çš„é©ç”¨æ€§

---

## ğŸ“š åƒè€ƒè³‡è¨Š
- **PMID**: [40963861](https://pubmed.ncbi.nlm.nih.gov/40963861/)
- **DOI**: https://doi.org/10.3389/fonc.2025.1601529
- **æœŸåˆŠ**: Frontiers in oncology
